Process Optimization of a DNA Minivector Production System

当前项目的目标是与目前的过程工程公司MemBio合作，优化生产和纯化高需求DNA微型载体的纯化工艺。DNA微型载体是线性共价闭合(LCC)分子，称为DNA Serings或msDNA。更安全的DNA载体具有高稳定性、高效性和高效纯化的特点，在基因/细胞治疗行业中作为运送基因货物的遗传载体的需求很高。该项目的成功完成将产生用于物理和生物化学优化msDNA生产的专有处理知识产权，并使他们能够为中试规模的测试做好准备。该项目的成功还将通过开发一种可在国内和国外实施的制造工艺来加强加拿大的生物经济。到目前为止，LCC DNA从其他DNA物种中分离出来，无论是大小还是拓扑结构，都还没有超过分析水平的纯化。为了推动基因医学的新发展，需要一种高效和大规模的方法来产生msDNA和其他类似的LCC DNA产物的镁尺度。这项提议寻求实施生化、遗传和物理策略，通过现有的最具成本效益的方法来纯化msDNA，并为MemBio在msDNA和其他微型载体DNA生产中产生新的能力。

The objective of the current project is to collaborate with a current process engineering firm, MemBio to optimize a purification process for production and purification of a high demand DNA minivector generation. The DNA minivectors are linear covalently closed (LCC) molecules known as DNA ministrings or msDNA. Safer DNA vectors with high stability, efficacy and efficient purification are in high demand in the gene/cell therapy industry as a genetic vector for delivery of genetic cargo. Successful completion of this project will generate proprietary processing intellectual property for physically and biochemically optimizing msDNA production and allow them to get it ready for pilot-scale testing. The success of the project will also help strengthen Canadian bio-economy by developing a manufacturing process that can be implemented nationally, and abroad. To date, separation of LCC DNA from other DNA species, both by size and topology has yet to be achieved beyond analytical levels of purification. An efficient and scaled-up approach to generation of mg scale of msDNA and other similar LCC DNA products is needed to drive new developments in genetic medicine. This proposal seeks to implement biochemical, genetic and physical strategies to purify msDNA through the most cost-effective approaches available and generate novel capabilities for MemBio in msDNA and other minivector DNA production.